Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues
Royalty revenue	$ 2,193,213	$ 4,333,500
Grant and contract revenue	2,276,796	2,053,384
Total revenue	4,470,009	6,386,884
Operating expenses
General and administrative	4,331,950	2,646,329
Research and development	8,823,179	4,088,187
Sales and marketing	2,676,590	997,574
Royalty expense	426,256	979,466
Total operating expenses	16,257,975	8,711,556
Loss from operations	(11,787,966)	(2,324,672)
Other income (expense)
Interest income	5,094	3,199
Interest expense	(420,890)	(536,886)
Gain on foreign exchange	15,932	14,129
Total other income (expense)	(399,864)	(519,558)
Loss before income taxes	(12,187,830)	(2,844,230)
Income tax expense	0	0
Net loss	(12,187,830)	(2,844,230)
Other comprehensive loss:
Foreign currency translation adjustment	(27,150)	12,501
Comprehensive loss	$ (12,214,980)	$ (2,831,729)
Net loss per share of common stock:
Basic (in dollars per share)	$ (2.43)	$ (0.66)
Diluted (in dollars per share)	$ (2.43)	$ (0.66)
Weighted average shares outstanding used to compute net loss per share:
Basic (in shares)	5,015,262	4,282,923
Diluted (in shares)	5,015,262	4,282,923